Table 3.
A list of strategies using transduced MSCs as an anticancer therapy for osteosarcoma.
| Anti-cancer agent | Sarcoma model | Therapeutic strategy | Mechanism of action | Study type |
|---|---|---|---|---|
| TRAIL | Osteosarcoma, Ewing's [140] | Cytotoxic agent | Apoptosis, Anti-angiogenic action | In-vitro and in-vivo animal studies |
| Ewing's [144] | Cytotoxic agent | Apoptosis | In-vitro and in-vivo animal studies | |
| OPG | Osteosarcoma [207] | Cytotoxic agent | Reduction of tumour growth and bone destruction caused by osteosarcoma cells | In-vitro and in-vivo animal studies |
| CD/5-FC | Osteosarcoma [132] | Gene-directed enzyme-producing therapy | Inhibition of DNA and RNA synthesis of tumour cells | In-vitro and in-vivo animal studies |
| IL-12 | Ewing's [156] | Cytotoxic agent | Inhibition of tumour growth | In-vivo animal studies |
Anti-cancer agents:
TRAIL: Tumour necrosis factor related apoptosis-inducing ligand, OPG: Osteoprotegerin CD/5-FC: Cytosine deaminase/ 5-fluorocytosine IL-12: interleukin-12.